Halo 110
Halo 110 is a single premixed vial pairing GHK-Cu (100 mg) with KPV (10 mg) for 110 mg total in a 5 mL vial — the copper-forward sibling of the 60 mg Halo / Beauty Blend (50 / 10 mg in 3 mL). Research protocols dose it by insulin units, starting around 8 units and building toward 25 units (5 mg GHK-Cu plus 0.5 mg KPV per day) subcutaneously.
Best for
Adults already familiar with GHK-Cu + KPV who want a higher copper share in a larger vial.
It pairs GHK-Cu's research on wound healing, skin regeneration, collagen and elastin synthesis and hair-follicle support with KPV's research on gut and systemic inflammation — at a 10:1 ratio, so it leans further toward the skin and copper side than Beauty Blend. Because its concentration differs from the 60 mg vial, it is a poor place to reuse unit numbers quoted for that one.
What to expect
Research on the individual components describes gradual changes rather than acute effects: skin- and collagen-related GHK-Cu effects are typically characterized over several weeks of repeated exposure, and KPV's anti-inflammatory effects in preclinical models emerge over days of repeated administration. No validated human time-to-effect for the blend is established.
Pairs with
Within this product GHK-Cu and KPV are already combined; in broader research practice both are grouped with recovery- and regeneration-oriented peptides such as BPC-157 and TB-500 (as in the GLOW and KLOW blends). Do not run it alongside a separate GHK-Cu vial or another copper blend without counting the copper together.
Premixed GHK-Cu + KPV blend (110 mg / 5 mL = 22 mg/mL: GHK-Cu 20 mg/mL + KPV 2 mg/mL), dosed by VOLUME.
The ladder is read in mg per component: 8 units on a U-100 syringe for maintenance (about 1.6 mg GHK-Cu and 0.16 mg KPV), 17 units for recovery (3.4 / 0.34 mg) and 25 units for healing (5 mg GHK-Cu — the daily research ceiling for copper — and 0.5 mg KPV), subcutaneously. The same unit draw here carries 20% more copper and 40% less KPV than a 60 mg / 3 mL vial, so check which vial you hold.
GHK-Cu can sting — let the filled syringe reach room temperature (~20 min) before injecting.
- How often
- Daily
- Route
- Subcutaneous
- Vial & water
- 110 mg in 5 mL · 8 units ≈ 1.6 mg GHK-Cu + 0.16 mg KPV
- Cycle
- Often run in 10-20 day courses with a break, or continuously for skin/hair support - your call. Copper stings, so build the dose up slowly.
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
Halo 110 is a single premixed vial combining two research-grade peptides — GHK-Cu (100 mg) and KPV (10 mg), for 110 mg total in a 5 mL vial.
GHK-Cu is a copper(II)-binding tripeptide (glycyl-L-histidyl-L-lysine) found naturally in human plasma, saliva and urine; research characterizes it as a signaling and copper-carrier peptide that modulates the extracellular matrix — stimulating collagen, elastin, glycosaminoglycan and decorin synthesis while modulating matrix metalloproteinases during tissue remodeling — with antioxidant and anti-inflammatory gene-level effects and research interest in hair-follicle health. KPV is a synthetic tripeptide (Lys-Pro-Val) matching the C-terminal residues 11-13 of alpha-melanocyte-stimulating hormone; research characterizes it as retaining much of alpha-MSH's anti-inflammatory signaling without its pigment-stimulating activity, with reported inhibition of NF-kappaB and MAP-kinase pathways and lower TNF-alpha and IL-6.
No study of this combination exists, and neither peptide is FDA-approved for human use, so this is strictly a research-context blend; the copper can sting at the injection site, so let the filled syringe reach room temperature (about 20 minutes) and inject slowly.
References4
- Pickart L, Margolina A - Regenerative and Protective Actions of the GHK-Cu Peptide, Int J Mol Sci
- Pyo HK et al. - The effect of tripeptide-copper complex on human hair growth in vitro, Arch Pharm Res (PubMed 17703734)
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (mouse model)
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (murine model)
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.